Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients with TP53-mutant AML

Dr Naval Daver speaks to ecancer in an online interview for the virtual EHA 2020 meeting. He describes the background, study design and results of this phase 1B trial, which investigated the combination magrolimab and azacitidine in patients with untreated…

Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients with TP53-mutant AML

Source

0
(0)

Dr Naval Daver speaks to ecancer in an online interview for the virtual EHA 2020 meeting.

He describes the background, study design and results of this phase 1B trial, which investigated the combination magrolimab and azacitidine in patients with untreated acute myeloid leukaemia (AML) and a TP53 mutation.

Dr Daver concludes that this novel treatment combination is well tolerated and effective in patients who are unfit for chemotherapy.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

0 / 5. 0

Leave a Reply

Your email address will not be published. Required fields are marked *